The days of being left behind with a minimal share of medicine sales have gone by. With the first black numbers ever and money to spend, Genmab is headed into a new phase, set to earn the Danish biotech a higher place in the pharma hierarchy, according to the CEO.
New products, new acquisitions, and a larger number of more efficient cost savings – all these elements have to come together for William Demant to keep delivering high growth rates, says CEO Niels Jacobsen. But acquisitions and profit are bound to slow down in 2014.
Novo Nordisk’s chief researcher welcomes the arrival of Eli Lilly as a worthy rival on a market that has so far been dominated by the Danish company’s drug Victoza. The rival could lead the way for Novo, he says.
Danish businessman Sonnich Fryland and his sister bagged millions from selling the vitamin company Ferrosan twice. Now, their tax evation efforts have triggered a claim of USD 20.5 million from the Danish tax department.
A new study has shown that candidate drug dulaglutid from Eli Lilly is on par with Novo Nordisk drug Victoza in terms of efficacy, but the US-based company refrains from commenting on one crucial aspect.
Bavarian Nordic has struck a new deal with the US government for the development of a vaccine against two potential biological threats. It signals broader collaboration with the Americans and broader use of the company’s technology, says CEO Anders Hedegaard.
Danish drug group Lundbeck struck a research deal with US biotech company Ossianix recently – a company that deals in something as novel as shark antibodies. Lundbeck’s Danish research chief is impressed with the US outfit.
The Danish medtech company Sense has bumped into some technological difficulties. An outright sale of the entire technology platform could be underway, according to Chairman of the Board and former Ambu executive Kurt Erling Birk.
For the first time in years, Exiqon has made massive investments in order to launch a new initiative - which has taken its toll on profits - but it should help to drive up growth significantly, says the company's CEO.
With an updated product portfolio, Danish drug group Lundbeck has entered into a competitive situation that is markedly different than the one seen in the company’s golden era with blockbuster Lexapro, says CEO Ulf Wiinberg.
A prosthetic hand that enables its owner to feel a handshake for the first time has yet to garner commercial interest, but a chunk of money from the EU is set to change all that, says a Danish scientist.
Prosthetics company Össur saw a great end to 2013 and the company’s CEO is very pleased with the development in the final quarter of the year. He expects an even higher growth in 2014, but a lot is riding on US customers.
CEO Lars Marcher is proud and pleasantly surprised by Ambu’s ability to lift the gross margins of three recently acquired companies to the group’s own level. But the US medtech tax – which, he says, is decidedly un-American – weighs down on operations.
One of the world’s biggest pharma players has shelved its sternly criticized sales methods to avoid having its integrity questioned due to unethical financial incentives, which could ultimately prove harmful to patients. But Novo Nordisk, Lundbeck and Leo Pharma are standing up for those very same methods.
Candidate drug Brexpiprazole is the diamond in the rough in Lundbeck’s pipeline, say analysts. The blockbuster candidate, which is used to treat mental disorders, is expected to hit the market as early as 2015.
It is one thing that the potential in Genmab’s deal with Janssen has been doubled, but another crucial aspect of the deal is that it has a “huge impact” on the company’s future prospects, says Jan van de Winkel.